FindTrial
Sign In

To see how Methylene blue drug which is used to increase O2 saturation levels, is helpful in treating Covid 19 patients.

An Observational pilot study to determine the effectiveness of Methylene Blue treatment in Covid 19 patients

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2021/04/033142
Enrollment
10
Registered
2021-04-27
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: B972- Coronavirus as the cause of diseases classified elsewhere

Interventions

Intervention1: Methylene blue injection: 1 mg/kg of Methylene blue injection given to covid 19 patients to treat Methemoglobinemia.

Sponsors

DR SMITHA K S
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1) Confirmed case of Covid 19 (RT-PCR) 2) Admission to Intensive care unit 3) Sex-Males and Females 4) Age- 18 to 90 years old. 5) Need for Oxygen support ( HFNC, NIV) 6) Respiratory rate (RR) between 20 to 30 7) SpO2 between 8) PaO2/FiO2 9) Written informed consent

Exclusion criteria

Exclusion criteria: Pregnancy and breastfeeding 2) History of G6PD deficiency 3) Severe renal insufficiency (GFR 4) Medical records of Cirrhosis 5) Active or Chronic Hepatitis 6) History of allergy to Methylene blue 7) Patients on immunosuppressive agents. 8) Patients exposed to aniline dyes and Dapsone

Design outcomes

Primary

MeasureTime frame
To observe the effects of Methylene blue treatment in Covid 19 patients.Timepoint: 7 days—

Secondary

MeasureTime frame
To record side effects of Methylene blue treatment in covid 19 patientsTimepoint: 30 days—

Countries

India

Contacts

Public ContactDR SMITHA K S

Bangalore Medical College and Research Institute.

smi9685@gmail.com9886935506

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026